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Abstract
We present the analysis of twenty human genomes to evaluate the prospects for identifying rare functional variants that
contribute to a phenotype of interest. We sequenced at high coverage ten ‘‘case’’ genomes from individuals with severe
hemophilia A and ten ‘‘control’’ genomes. We summarize the number of genetic variants emerging from a study of this
magnitude, and provide a proof of concept for the identification of rare and highly-penetrant functional variants by
confirming that the cause of hemophilia A is easily recognizable in this data set. We also show that the number of novel
single nucleotide variants (SNVs) discovered per genome seems to stabilize at about 144,000 new variants per genome,
after the first 15 individuals have been sequenced. Finally, we find that, on average, each genome carries 165 homozygous
protein-truncating or stop loss variants in genes representing a diverse set of pathways.
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Introduction
The technology to sequence entire human genomes has evolved
rapidly in recent years. Massively-parallel sequencing techniques
have been developed, and it is now possible to sequence an entire
human genome in little more than a week. Programs to align these
short reads and call the resulting variants are being developed and
optimized [1,2], and the cost to sequence a genome has
plummeted. Single human genomes have been sequenced on a
number of different next-generation sequencing platforms [3–6].
Whole genome sequencing has also been used to identify rare,
disease-causing variants by sequencing the genome of one or a
small number of affected individuals and then performing
necessary follow-up work to confirm the variant [7-9], and it has
also been used to study the patterns of variation that develop in
cancerous cells [10,11].
It will be essential going forward to be able to characterize the
patterns of variation in larger sets of sequenced genomes. As a
first step in that direction, we have characterized the patterns of
variation observed in 20 human genomes that were sequenced
at high coverage using the Illumina Genome Analyzer IIx
platform.
Results
Study population
We sequenced individuals with hemophilia A who were thought
to have been exposed to HIV-1, and who will contribute to a
larger future study to identify genetic determinants of resistance to
infection with HIV-1. We also considered ten genomes from
various other non-HIV- related projects (Table S1), hereafter
referred to collectively as ‘‘controls’’ for convenience. The ten
hemophilia patients are all of European ancestry, as are seven of
the controls. Two of the controls are Hispanic and one control is
African American. This was confirmed using a principal
component analysis [12].
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The DNA for this study was extracted from blood samples or
peripheral blood mononuclear cells (PBMCs). For each sequenced
genome, we aimed to produce 70–80 billion bases that passed
Illumina’s quality filters. Some individuals were sequenced at
much higher coverage (about 150–200 billion bases) to assess how
coverage affects variant calling. To determine overall coverage, all
gaps (stretches of N’s) in the reference genome (NCBI human
genome assembly build 36; Ensembl core database release 50_36l
[13]) were excluded, resulting in the reference having
2,855,343,769 bases. After accounting for PCR duplicates and
reads that did not align to the reference genome, genomic
coverage of the autosomes ranged from 206to 516(Table 1). We
further defined a ‘‘covered’’ base as a base with at least five reads
where the Phred-like consensus score was greater than zero. On
average across the autosomes, 97.45% of the reference genome
was covered with at least five reads at each base, with a range of
92.49% to 99.65% coverage across the 20 genomes (Table 1).
Identifying single nucleotide variants (SNVs), small
insertion/deletions (indels) and copy number variants
(CNVs)
The short-reads were aligned with the Burrows-Wheeler
Alignment tool (BWA) [1], and the genetic differences between
our sequenced genomes and the reference were identified using
modified settings in the SAMtools variant calling program [2]. On
average, we identified approximately 3.5 million SNVs and
610,000 indels per genome (Table S2). Over 87% of the SNVs
identified in each of the 20 genomes were found in the dbSNP
database (Figure 1, Table S3), similar to what has been seen in
other reports (Table S4), and 43.45% are in the HapMap project
database (Table S3) [14]. The number of indels we observed is also
similar to other reports (Table S5), although there were only a
limited number of indels included in dbSNP (n=13,727, version
Author Summary
We report here the nearly complete genomic sequence of
20 different individuals, determined using ‘‘next-genera-
tion’’ sequencing technologies. We use these data to
characterize the type of genetic variation carried by
humans in a sample of this size, which is to our knowledge
the largest set of unrelated genomic sequences that have
been reported. We summarize different categories of
variation in each genome, and in total across all 20 of
the genomes, finding a surprising number of variants
predicted to reduce or remove the proteins encoded by
many different genes. This work provides important
fundamental information about the scope of human
genetic variation, and suggests ways to further explore
the relationship between these genetic variants and
human disease.
Table 1. Summary of genomic and exonic coverage in the twenty sequenced genomes.
Individual ID
Covered Genomic
Bases (autosome)
% Covered Genomic
Bases (autosome)
Genomic Coverage
(autosome)
Covered Exonic
Bases (autosome)
% Covered Exonic
Bases (autosome)
Exonic Coverage
(autosome)
hemo0001 2,670,818,496 99.61% 30.46 63,569,350 97.10% 26.66
hemo0004 2,546,304,227 94.97% 23.06 63,738,611 97.35% 26.26
hemo0005 2,575,871,501 96.07% 36.26 64,204,173 98.06% 48.46
hemo0006 2,626,377,905 97.95% 51.06 64,757,369 98.91% 67.76
hemo0007 2,545,912,138 94.95% 34.26 63,830,877 97.49% 44.66
hemo0011 2,479,945,673 92.49% 31.66 63,061,145 96.32% 46.36
hemo0017 2,636,817,553 98.34% 33.46 64,562,534 98.61% 38.66
hemo0019 2,523,147,259 94.10% 20.26 62,931,312 96.12% 22.76
hemo0020 2,616,985,451 97.60% 36.46 64,558,006 98.61% 45.26
hemo0022 2,589,531,152 96.58% 38.76 64,325,506 98.25% 49.06
Control 1 2,672,018,880 99.65% 32.36 64,680,869 98.79% 32.56
Control 2 2,669,408,111 99.56% 28.06 64,622,306 98.70% 28.46
Control 3 2,636,454,707 98.33% 23.66 62,016,800 94.72% 21.76
Control 4 2,665,796,091 99.42% 30.56 64,770,818 98.93% 32.96
Control 5 2,626,655,211 97.96% 27.46 63,742,412 97.36% 27.96
Control 6 2,599,845,577 96.96% 24.96 63,583,260 97.12% 26.06
Control 7 2,637,966,004 98.38% 23.36 62,924,185 96.11% 21.66
Control 8 2,621,651,349 97.78% 26.96 64,136,845 97.96% 27.06
Control 9 2,672,035,152 99.65% 39.06 63,992,418 97.74% 35.36
Control 10 2,642,657,667 98.56% 31.46 63,867,622 97.55% 31.86
Average 2,612,810,005 97.45% 31.16 63,893,821 97.59% 35.06
Coverage was defined as the percentage of bases in the genome/exome that have at least 5 reads with a Phred-like consensus score of greater than zero at that
position. The total size for the autosomal genome is 2,681,301,098 bp, which is the total reference length of the autosomes (NCBI human genome assembly build 36)
minus the reference sequence gaps (‘N’ calls in reference sequence). The total size for the autosomal exons is 65,471,109 bp, which is the total length of the autosomal
exons, defined as all protein coding gene entries in Ensembl core database version 50 [13]. The Ensembl database version 50 is based on the NCBI human genome
assembly build 36 as well as its annotations (GeneBank).
doi:10.1371/journal.pgen.1001111.t001
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informative. The average transition to transversion ratio is 2.08
and average homozygote to heterozygote ratio is 0.59 (Table S6),
both consistent with what has been reported previously [3,15,16]
(Table S7).
We used the genomic distribution of the number of aligned
reads (read depth) to infer copy number state in 2 kb windows
using a hidden Markov model approach, incorporating SNV
genotype status, implemented in a software package called
‘‘Estimation by Read Depth with SNVs’’ or ERDS [17]. We
predicted 5,821 distinct copy number variants (CNVs) on the
autosomes (6,204 across the whole genome) that were greater than
2 kb in length, and that had unique start and stop coordinates (we
note, however, that even the same CNV will often be inferred to
have slightly different start and stop points, meaning that it is in
general not possible to determine which CNVs are identical across
samples using only the location information). There was an
average of 338 deletions (covering 0.72% of the autosomes) and
411 duplications (covering 0.79% of the autosomes) per genome.
The median (mean) size of these CNVs was 34kb (58kb) [17]. We
further note that this method is designed to detect test genomes
that differ from the reference genome in genomic regions that are
present in normal or nearly normal copy number state in the
reference genome (corresponding to having a copy number count
of two in typical genomic regions). ERDS is not designed to
provide an absolute count for heavily amplified regions of the
genome and in its current implementation will be insensitive to
quantitative differences in highly amplified regions in comparison
with the approach embodied, for example, in MrFAST [18].
Comparison of identified SNVs and CNVs to results from
genotyping chip data
All samples were also run on either the Illumina Human1M-
Duo version 3 or 610-Quad genotyping BeadChip, allowing
comparison of SNV calls between the platforms, as well as
comparison of structural variant calling. To assess concordance for
SNVs, we considered all variants present on the relevant
BeadChip: the concordance rate between sequencing and
genotyping SNV calls ranged from 97.11% to 99.33% with an
average rate of 98.58% (Figure 2, Table S8). To investigate the
discordant SNVs in more detail, we split the discordant SNVs into
two groups: category 1- SNVs with homozygous calls by
sequencing, but heterozygous call by genotyping BeadChip; and
category 2- any other mismatch. The majority (around 70%) of
discordant calls were category 1 and preferentially observed at
low-coverage sites. Category 2 discordance likely represented a
mix of sequencing and genotyping errors.
We next compared structural variants called by ERDS with
structural variants inferred from the BeadChip data using
PennCNV [19]. Visual inspection of the BeadStudio data makes
clear that the majority of discrepancies between ERDS and
PennCNV calls for CNVs are due to the lack of sensitivity of
PennCNV and the challenges in using chip data to call CNVs,
especially small CNVs. Given these limitations, only 49.8% of the
PennCNV-called CNVs are visually validated in BeadStudio, and
only 11.7% of the deletions called by both ERDS and Break-
Dancer [20] can be detected by PennCNV. We also implemented
several other key comparisons. First, we checked in our sample for
common CNVs described by McCarroll et al [21] that have
associated tagging SNVs. We checked for the presence of tagging
SNVs, which indicated that the corresponding CNVs should be
Figure 1. Average per-genome overlap between SNVs in genomic databases and SNVs identified by whole-genome sequencing. On
average, 3,473,639 SNVs were observed in each genome (Table S2). A per-genome average of 87.28% of these SNVs were present in the dbSNP
database (version 129, validated) (Table S3).
doi:10.1371/journal.pgen.1001111.g001
Figure 2. Concordance between sequencing and genotyping
calls. The sequenced samples were also run on either the Illumina
Human 1M-Duo v3 BeadChip or the Illumina 610-Quad BeadChip. The
concordance rate between the sequencing and the Illumina BeadChip
genotype calls is plotted against sequencing coverage of the
autosomes. A data point is plotted for each of the twenty genomes.
doi:10.1371/journal.pgen.1001111.g002
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were called in our samples by PennCNV and ERDS, and we
found that 9.8% (62/631) of such tagged CNVs were called by
PennCNV, and 54.7% (345/631) were detected by ERDS.
Furthermore, on average 43.1% of the ERDS-called CNVs had
at least a 50% overlap with a common CNV entry in the Database
of Genomic Variants (DGV) [22]. For those ERDS called CNVs
that have been reported to be tagged by particular SNVs [21],
74.3% (371/499) of the corresponding SNVs are present in the
genomes shown to carry the relevant CNV [17].
Evaluation of functional categories of identified variants
In order to classify variants in terms of functional potential, we
developed a software environment called SequenceVariantAnaly-
zer or SVA [23] (http://www.svaproject.org/), which is a JAVA-
based set of software tools that provides visualization and
functional annotation of the called variants (Text S1). In
particular, SVA is able to group the identified variants into
functional classes (for example, non-synonymous, synonymous,
stop gain), and to carry out simple frequency comparisons either
internally (using our cases and controls) or externally, using, for
example, data from HapMap [14] or the 1000 Genomes Project
[24]. SVA can also filter for variants that meet certain quality
control measures, or for genes in a certain pathway or gene
ontology, or genes that are thought to have a certain function (for
example, only protein-coding genes), or genes in a user-created list
(for example, candidate genes based on user-defined criteria).
Using this tool, we evaluated the quantity of polymorphisms in
different genomic regions, including intergenic, intronic, intron-
exon boundary and exonic (Figure S1, Text S1). We also used
SVA to characterize the numbers of variants in key functional
categories including stop gain, stop loss, and nonsynonymous
SNVs (Table S9) and frameshift coding indels (Table S10). Of
particular note were variants that result in the truncation of a
protein product. We define protein-truncating variants throughout
this study to be any SNV that results in the gain of a stop codon,
and any indel that results in a frameshift coding change. We also
report some analyses that combined SNVs that result in the loss of
a stop codon with those resulting in truncation to focus on a set of
variants affecting the integrity of the protein product. We chose to
evaluate these types of variants here and in subsequent analyses
since they would be predicted to have the largest effect on protein
activity. On average, each genome had 165 homozygous variants
that were protein truncating or resulted in the loss of a stop codon
(Tables S9 and S10). Across all 20 genomes we observed 563
different variants that were predicted to cause premature stops
(n=123), loss of a stop codon (n=24), or a frameshift change
(n=416) in the coding regions of 484 unique genes, and which
were predicted to be carried in their homozygous form by at least
one of the twenty individuals. Out of these 563 variants located in
484 different genes, 21 variants, located in 20 genes, were
observed in all 20 genomes. These may indicate that a less
common allele is represented in the reference genome, or that the
reference represents an error in the original sequencing of the
human genome.
The number of protein-truncating or stop loss variants that we
observed per genome was greater than what has been observed in
studies that have sequenced whole exomes. Part of the reason is
that we used the Ensembl transcript designations (Ensembl
database versions 50_361) to screen for protein-truncating or stop
loss variants. This database includes many putative protein-
encoding genes that have not been confirmed to make a protein.
We opted for this inclusiveness because of the possibility that
poorly characterized transcripts may be of importance. For the
purpose of comparison, however, we also evaluated the number of
homozygous protein-truncating or stop loss variants that fell within
the regions captured by the Agilent SureSelect Exome Targeted
Enrichment system and that are in canonical transcripts. The
number of coding indels and frameshift indels was similar to what
has been observed previously [25] (Table S11).
We performed a pathway analysis using the Ingenuity Pathway
Analysis (IPA) software to determine if the set of homozygous
protein-truncating or stop loss variants were enriched for specific
pathways. For this analysis we excluded the 21 variants present in
all 20 genomes. The removal of these 21 variants removed 17
genes from our analysis. Of the remaining 467 genes, 330 were
recognized by the HUGO Gene Nomenclature Committee
(HGNC) database [26], and contained 364 unique homozygous
protein truncating or stop loss variants. Of these, there were 228
genes with known functions (defined as a known gene ontology
annotation; n=50 for genes with premature stop SNV; n=7 for
genes with stop loss SNV; n=177 for genes with frameshift indels).
One gene has both a stop gain and a stop loss SNV, and five genes
have both a stop gain SNV and a frameshift indel. The analysis
did not result in a single significant canonical pathway. The most
common genes with known functions were olfactory receptor
genes (n=32), followed by different protein-binding and DNA-
binding genes. The enrichment of protein-truncating or stop loss
variants in the olfactory receptor genes is not surprising because
they make up a large gene family that is highly polymorphic for
‘‘pseudogenizing’’ polymorphisms [27]. Anything that is annotated
as a pseudogene in Ensembl, including those in the olfactory
receptor family, has not been included in this analysis.
Size and type of identified coding indels
We checked the size distribution of the coding indels that we
observed in the study. The majority of the coding indels in our
dataset were multiples of 3bp (51%), similar to what has been seen
in other studies [28] (Figure 3).
We found 2,865 indels that cause a frameshift change and 3,737
coding indels that do not cause a frameshift change across our 20
genomes (Table S10). On average, we found 609,795 indels per
genome, including 132 homozygous frameshift coding indels and
239 homozygous non-frameshift coding indels with at least 106
coverage at the variant positions (Tables S2 and S10). We also saw
that the version of SAMtools that was used to make the variant
calls had a large effect on the zygosity of the indels that were called
(Table S1, Table S10). Inspection of discordant calls between the
SAMtools versions showed that neither version was uniformly
more accurate than the other.
Location of protein-truncating SNVs and indels
We investigated the locations within genes of the 554 identified
stop gain SNVs and 2,865 frameshift indels. Consistent with
previous reports [28], we found that these protein-truncating
variants were not randomly located within genes, but rather
enriched at both the N-termini and the C-termini, with a slightly
higher frequency at the C-termini of the relevant proteins (Figure
S2). We observed the same trend for both homozygotes and
heterozygotes (data not shown).
Duplicated sequence can create apparent
polymorphisms
On average, 11.2% of variants identified on the X-chromosome
are assigned a heterozygote status in males (n=17 males, Table
S1). We investigated this phenomenon and found that 48.5% of
them are in the pseudoautosomal regions (PARs), which are
Characterization of Twenty Sequenced Human Genomes
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Y-chromosome PARs are free to align to the X-chromosome since
there is no Y-chromosome PAR target. Because of the divergence
between the chromosomes however, alignment of Y chromosome
PAR sequence to the X chromosome can lead to variants being
called. We found that 93.1% of this region is called as duplicated
by ERDS in males. An additional 18.3% of the heterozygous
SNVs on the X-chromosome in males fell in the parts of the
centromeric regions that were not masked in the reference
sequence, and which also appear as a duplicated region according
to ERDS. The remainder of the heterozygous SNVs that were
called on the X-chromosome in males may fall within the limits of
a CNV that is too small to be picked up by ERDS, where the read
depth signal is not strong enough to call as a duplication, or in
amplified genomic regions that cannot be accurately identified as
such using the ERDS approach.
While immediately recognizable on the X-chromosome in males,
there is of course no reason that this phenomenon is restricted to the
X-chromosome. To investigate the extent to which duplicated and
diverged sequence contribute to called variants elsewhere in the
genome, we note that when this happens, an excess of heterozy-
gosity is likely and the genotype distributions will often be far out of
Hardy-Weinberg equilibrium (HWE). For the autosomes, we
therefore calculated HWE by Fisher’s exact test for all SNVs for
the whites in this study (n=17, Table S1). We then focused on those
polymorphisms with a p-value less than 0.01 in terms of where they
fell across three distinct genomic regions: A) Genomic regions
inferred to be duplicated in all samples relative to reference. B)
Genomic regions inferred to be duplicated in one or more (but not
all) samples. C) Genomic regions inferred to be in a non-duplicated
region for all samples. We found that 0.72% of polymorphic loci
(63,550/8,838,651) were not in Hardy-Weinberg equilibrium in the
directionofexcessheterozygote calls.Ofthoseoutliers,72.0%fall in
category A), which only encompassed 0.41% of genomic length of
autosomes. This indicates that outliers of HWE were highly
concentrated in duplication regions. An additional 11.2% of the
variants fell into category B, which encompassed 1.16% of the
autosomes. The remaining variants (16.8%) fell into category C,
which encompassed the remaining 98.43% of the autosomes.
Experimental evaluation of a subset of the identified
variants
We then used Sanger sequencing to evaluate a subset of identified
protein-truncating variants. For this evaluation, we randomly
selected 10 premature stop SNVs and 10 frameshift indels that
appeared in homozygous form in multiple samples, and then
evaluated the relevant genomic regions by Sanger sequencing in 16
samples (sufficientDNAforthefollow-upworkwasavailable inonly
16 of the 20 samples). Of the ten SNVs that we selected for
evaluation, 8 were 100 percent concordant for all genotype calls
across all samples between next-generation sequencing (NGS) and
Sanger sequencing (Table S12). One variant occurred in a region of
very high coverage (greater than 10006), which is known to
produce variantcalling errors [29]. (We note that as the appropriate
threshold for excluding variants due to high coverage is unclear, we
carried all variants into SVA regardless of coverage and filtered at
that point.) The final variant was concordant for all but two samples
(where variants were called as heterozygotes by Sanger sequencing
butwere calledashomozygotesbyNGS,whichisthemostcommon
SNV calling error (category 1, as described above). Excluding the
high-coveragevariant,ourconcordance rate forSNVgenotype calls
was 130/132 (98.5%). For the indels selected for evaluation, 7
variants were successfully sequenced, and 5 of these showed perfect
concordance between NGS and Sanger sequencing for all genotype
calls that pass our filters (Table S12). Two indels were incorrectly
called, but closer inspection reveals the complexity of calling these
two indels. For one of these, Sanger sequencing identified two indels
within 12bp of one another. Both variants were called by SAMtools
[2], but by default, when there is more than one indel within a 30bp
window, SAMtools variant filtering will drop whichever indel has
the lower quality score. The region containing the final indel also
contains two SNVs, and the combined genotypes of these three
variants sometimes made the region difficult to align and call
properly. In total, we validated the genotype calls at 83/101 indels
(82.2%),spreadoverthese7variantsinthe16samples.Importantly,
althoughindelgenotypecallswere inaccuratefortwoofthe indelsin
a subset of the samples, all 7 indels identified by NGS were
confirmed to be real indels in the predicted location by Sanger
sequencing.
Figure 3. Coding indel length distribution. Shown is a side-by-side comparison of the length of the coding indels in this study as compared to a
previous publication [26]. (A) Indel lengths observed in J.C. Venter’s exome [26] versus (B) indel lengths observed in this study. The data from our
study have been restricted to the canonical genes or transcripts that are captured by the Agilent SureSelect Targeted Enrichment system. Indels that
are a multiple of 3bp in length are marked in green.
doi:10.1371/journal.pgen.1001111.g003
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called overall in this dataset using other experimental methods. To
do this we identified a class of ‘‘vulnerable’’ SNVs as those that
passed our variant calling criteria and were 1) observed in just one
sample and 2) and were not listed in dbSNP. Of these
‘‘vulnerable’’ SNVs, we chose 20 at random. Since these SNVs
were likely to have a higher than average false positive rate, this
analysis should have given us a conservative estimate of how well
SNVs are being called overall. We genotyped these 20
‘‘vulnerable’’ SNVs by TaqMan in a total of 16 samples, including
the sample putatively carrying each variant. We used Illumina
Custom TaqMan SNP Genotyping Assays for genotyping. We
then assessed whether the SNV showed evidence of variability in
any of the samples, and if so, an individual blinded to the NGS
data identified which sample contained the variant. We found that
the genotypes we observed by TaqMan showed perfect concor-
dance with the genotype observed by NGS sequencing for 18 of
the 20 variants investigated. No variant was observed for the
remaining two assays. Thus, at least 18 of these 20 variants are
real, giving us a conservative estimate of 90% accuracy for calling
‘‘vulnerable’’ SNVs.
Comparison of cases to controls
To see whether we could easily identify the gene causing
hemophilia in the cases, we next tested for enrichment of specific
clearly functional variants in the set of 10 cases compared with the
10 controls. We identified first all protein-truncating or stop loss
variants in homozygous form on the autosomes or present on the
X chromosome, and we ranked all genes in the genome in terms of
the number of cases affected. A variant was included in these
counts as long as: 1) it was never observed in homozygous form in
the controls, 2) no other protein-truncating or stop loss variant in
the same gene was present in homozygous form in the controls, 3)
it had a minor allele frequency of less than 25% in the controls
(observed in heterozygous form in 5 or fewer of the 10 controls), 4)
it had a minimum of 106coverage on autosomes or 56coverage
on the sex chromosomes to be considered a homozygote, and 5)
the affected gene was present in the HGNC database [26].
Not surprisingly, the gene with the most affected cases was
Factor VIII (F8), mutations in which are known to cause
hemophilia A. In our study, six of the hemophilia patients had
identified protein truncating mutations (Table 2, Table S13,
Figure S3). Table S14 lists all genes that fit the criteria and have
protein-truncating or stop loss variants in at least 3 cases,
regardless of HGNC classification. We did not identify disease
causing mutations in the F8 gene for four of the hemophiliacs.
However, it is well documented that a particular large inversion
contributes to around 40% of all the severe type A hemophilia
patients [30,31]. Inversions are difficult to identify from short
sequencing reads using current analysis tools, and in the case of
F8, this is further complicated by regions of repetitive sequence
that flank the known F8 inversion.
We also determined how many controls would be required to
identify F8 in our 10 cases, by evaluating the rank of the F8 gene
as defined above. We found that once we had five controls, F8
consistently ranked among the top five genes that showed an
enrichment of variants in cases and not in the controls (Figure 4).
Furthermore, the identification of the cluster of variants in F8
served as a proof-of-concept, by demonstrating that the technical
and bioinformatic approaches that we used in this paper are
sufficient to identify rare disease-causing variants.
We next evaluated the scope for identifying specific coding
variants that show a significant enrichment in our designated
‘‘cases.’’ In our dataset, there are 39,374 coding SNVs or indels
that are present in at least two cases. Since variants in this class
would be more likely to influence traits of interest than variants not
annotated as functional, it seems reasonable to treat such groups of
functional variants as a separate class in association studies [32].
The maximum imbalance that a variant could show in the current
data set was to be present in the 10 cases and absent in the 10
controls, which would generate a p-value of 1610
25. However, a
Bonferroni correction for 39,374 tests requires a p-value of
1.3610
26 to be significant at a=0.05. Thus, it is not possible to
reach significance in this size dataset, even for maximally
imbalanced results.
Number of novel SNVs as a function of genomes
considered
Finally, we evaluated how many novel SNVs were identified as
the number of study subjects increased. Considering one of the
genomes at random, we found on average 443,000 SNVs not in
dbSNP. We then asked how many new SNVs were added per
genome, considering both variants in dbSNP and variants
‘‘discovered’’ in the previously considered genomes. We permuted
the order of genomes 1000 times and then took the mean of the
number of SNVs added at each incremental step. The number of
new SNVs per genome appeared to level off at around 144,000
novel SNVs by the 15
th genome (Figure 5A, Text S1).
We also considered the related question of how many new genes
have been observed to be ‘‘knocked-out’’ by homozygous protein-
truncating or stop loss variants per new genome that has been
sequenced. Again, we permuted the order of genomes 1000 times
Table 2. Prioritization of protein-truncating or stop loss variants enriched in hemophilia samples.
Rank Gene
# controls het (homo,
but with low coverage) SNV Count Indel Count Total Count Comment
1 F8 0 1 4 5 Visual inspection of the alignment shows a sixth
sample that also has a deletion in F8. It is called as a
heterozygote by SAMtools.
2 C16orf84 20 5 5
3 C8orf80 40 4 4
4 PRB1 2( +1) 4 0 4
5 EFCAB2 2( +1) & 0 0 3 3 2 variants. Both occur in the same cases, with the
same zygosity
Only canonical genes (with a defined HUGO Gene Nomenclature Committee (HGNC) database entry [26]) were included.
See Table S14 for a full list of genes.
doi:10.1371/journal.pgen.1001111.t002
Characterization of Twenty Sequenced Human Genomes
PLoS Genetics | www.plosgenetics.org 6 September 2010 | Volume 6 | Issue 9 | e1001111and then took the mean of the number of new genes added with
homozygous protein truncating or stop loss variants at each
incremental step. The number of new genes appeared to level off
around two new knocked-out genes per genome (Figure 5B).
Assuming about two newly identified ‘‘knock out’’ genes per new
genome sequenced, we may therefore estimate that sequencing
around 10,000 genomes (20,000 genes/2 genes per genome) would
be required to determine the number of genes that can be knocked
out and still be compatible with life. At this point, it is not possible
to more accurately estimate the true number of genomes that
Figure 4. Rank of the F8 gene as the number of control genomes increases. The gene ranking was ordered by the number of case genomes
that carried protein-truncating or stop loss variants, in homozygous form or on the X-chromosome, that were not present in control genomes in
homozygous form. Ranking was performed with a ‘‘gene prioritization’’ function implemented in the SVA software tool [21] (Text S1). Protein-
truncating variants were defined as SNVs that cause a premature stop codon, and insertions or deletions that cause a frameshift coding change. The
ranks represent an average taken from five permutations. When comparing 10 hemophilia cases to just one control, F8 ranks in the top 40 genes.
Once 5 or more controls are available, it ranks in the top 5 genes.
doi:10.1371/journal.pgen.1001111.g004
Figure 5. Number of novel SNVs and novel knocked-out genes as the number of genomes increases. The total number of novel variants,
and the total number of novel genes containing protein truncating or stop loss variants, continues to drop as additional genomes are added to the
analysis. Shown are the number of unique SNVs (A) and unique genes carrying a homozygous protein-truncating or stop loss variant (B) per genome,
as a function of the number of genomes already considered. The genomes were added in a random order to both analyses, and 1000 permutations
were performed and averaged.
doi:10.1371/journal.pgen.1001111.g005
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observed in 20 genomes, with the caveats that we don’t know how
the rate of variant discovery will behave after 20 genomes, and
given that we know that a portion of the protein-truncating indels
included in the analyses will be either mis-genotyped (above) or
artifacts. Nonetheless, it is clear that sequencing on the scale now
possible will slowly identify individuals carrying homozygote
knock-out mutations for a large catalogue of genes.
Discussion
Our evaluation of a broad range of overall coverage values has
allowed us to identify an appropriate target coverage for discovery
studies. Importantly, we found that once overall coverage exceeds
about 30–356, the concordance rate between sequencing and
genotyping stabilizes at greater than 98.58% (Table 1, Figure 2).
This suggests that between 30–356 is an appropriate target
coverage for accurate variant calling.
The identification of the F8 gene as the top ranking gene, in
terms of protein truncating genotypes, confirmed that the cause of
a Mendelian disease can be identified by next-generation
sequencing, as has been recently demonstrated by several groups
[7–9,25,33,34]. The majority of the causal mutations we observed
in F8 were indels, and it is known that indel calling using next-
generation sequence data is much less accurate than SNV calling
(see above, and [35,36]). Nevertheless, F8 is easily identified as
responsible for hemophilia. This is consistent with our recent
identification of a protein-truncating indel in the PTPN11 gene as
responsible for metachondromatosis, a rare Mendelian disease
affecting the skeleton [8]. Thus, even though indel calling remains
a work in progress, it is nevertheless sensible to keep them in
current variant calling pipelines.
Due to the limitations on obtaining whole-genome sequences to
use as a control cohort, a handful of phenotypes were present in
our controls (Table S1). However, they were still reasonable
controls to use in our study design, since they represented a
diversity of phenotypes and did not have hemophilia. Finally, the
fact that we were only able to identify the causal variant for
hemophilia in 6 out of the 10 patients also demonstrated the
current limitation of using a next-generation sequencing study to
identify certain types of genetic variants, including inversions.
The inclusion of 20 genomes in our analyses also allowed us to
evaluate the discovery rate of new variants as additional genomes
are added. Although the rate of variant discovery will continue to
fall at an unknown rate, this nonetheless gives us a rough idea of
how many genomes would be required to identify specific numbers
of variations (or genotypes). In these analyses, the observation of
greatest interest is that each genome carries many genes that are
not expressed (knocked-out) and that a manageable sequencing
effort of perhaps 10,000 individuals would allow the establishment
of a cohort of individuals that are effective ‘‘knock outs’’ for many
of the human genes which are not necessary for survival. It seems
likely that such a cohort could be used much as mouse knock outs
have been used, by inviting certain individuals to participate in
intensive phenotyping to determine the effect of specific gene
knockouts. Given the value of mouse knock outs in defining
pathways and interactions, it seems likely that such a cohort will in
time become a critical tool in human genetics. In addition, the
catalogue of genes that can be knocked out with specific clinical
consequences will also be of obvious immediate utility in the
burgeoning effort to use whole-genome sequencing of defined
cases to identify the genetic basis of common human disease,
although considerable care would be required in the selection of
the appropriate healthy controls for such a study.
Materials and Methods
Sample Preparation
Each sequenced sample was prepared according to the Illumina
protocols. Briefly, one microgram of genomic DNA was
fragmented by nebulization, the fragmented DNA was repaired,
an ‘A’ was ligated to the 39 end, Illumina adapters were then
ligated to the fragments, and the sample was size selected aiming
for a 350–400 base pair product. The size selected product was
PCR amplified, and the final product was validated using the
Agilent Bioanalyzer. Samples were then amplified on the flow cell
and sequenced using the Genome Analyzer IIx, following the
Illumina supplied protocols. The majority of sequence runs were
paired end with 75 base reads. We aimed for 70–80 billion bases
that passed the Illumina analysis filter per genome.
Analysis pipeline
All sequencing data was produced and curated by the Genomic
Analysis Facility, part of the Center for Human Genome
Variation, at Duke University. After the sequencing reactions
were complete, the Illumina analysis pipeline was used to process
the raw sequencing data (Firecrest, Bustard and Gerald). The
resulting Eland alignment was used only to estimate an error rate
for each read/cluster. If a sequencing run/lane had an error rate
above 2%, the run was considered a failure and the data was not
used. The quality of the sequencing runs were also assessed by
evaluating the percentage of clusters passing filter and the
percentage of reads that align to the reference genome. For a
typical run, over 70% of clusters pass filter and over 85% align.
Any major deviations from these values would trigger further
evaluation (average intensity, error graphs, etc) and likely lead to
these runs/lanes not being used. The FASTQ files were then
ready for the next alignment step.
Once the raw sequence data was curated, the reads were
aligned to a reference genome (NCBI human genome assembly
build 36) using the BWA software [1]. Each alignment was
assigned a mapping quality score by BWA, which is the Phred-
scaled probability that the alignment is incorrect. The PCR
amplification step will lead to the sequencing of identical DNA
fragments. Not removing these PCR duplicates can lead to the
miscalling of SNVs by overrepresentation of one allele. This is
corrected by a quality control step to remove these potential PCR
duplicates with SAMtools. Once all the reads have been aligned to
the reference genome using BWA [1], we then used the SAMtools
software [2] to produce a consensus genotype for each genomic
position. The consensus genotype is the genotype which has the
highest probability of occurring after consideration of a number of
factors [37]. Each consensus genotype is then assigned a consensus
quality, which is based on a Phred-scaled probability that the
genotype call is incorrect. Single nucleotide variants (SNVs) and
insertion/deletions (indels) were then identified based on differ-
ences between the consensus genotype and the reference allele at
that position. SAMtools also assigns a Phred-scaled probability to
each identified SNV/indel which indicates how likely it is that an
inferred SNV/indel is identical to the reference. These SNVs and
indels were then filtered by SAMtools’ variation filter, changing
only the maximum read depth parameter to call variants from its
default value (100) to 10 million, to prevent the exclusion of SNVs
and indels at a read depth greater than 100. The lists of SNVs/
indels were then annotated in the SequenceVariantAnalyzer (SVA
[23]). SVA was specifically designed to annotate the large number
of identified SNVs/indels using a number of human genomic
databases. In addition to looking at the SNVs/indels from the
BWA alignment/SAMtools, we also predicted larger structural
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SNVs’’ or ERDS method, based on a Hidden Markov Model [17].
This was an extension to the methods described in Bentley et al.
[3] and draft codes from Scally, A. [38]. Further details describing
the analysis tools are presented in Text S1.
Data access
The raw reads for a portion of the genomes used in this study
are available on the NCBI sequence read archive, under study ID
SRP001691 (http://www.ncbi.nlm.nih.gov/sra/SRP001691). We
do not have consent from the patients and/or permission from the
Duke IRB to release the raw reads for several of the genomes used
in this study.
Supporting Information
Figure S1 Location of identified variants observed across all 20
genomes. These graphs show the functional distribution of SNVs
(A) and indels (B) based on their location in relation to annotated
transcripts.
Found at: doi:10.1371/journal.pgen.1001111.s001 (1.65 MB TIF)
Figure S2 Position of protein truncating variants within coding
sequences. These graphs show the relative locations of stop-gain
SNVs (A) and frameshift indels (B) within protein-coding
sequences. A relative location near 0.1 (left side of x-axis) indicates
that the variant is near the N-terminus, while a location near 1.0
(right side of x-axis) indicates that the variant is near the C-
terminus. The y-axis is the absolute count of variants. Figures
include both homozygous and heterozygous variants from across
all 20 genomes.
Found at: doi:10.1371/journal.pgen.1001111.s002 (0.83 MB TIF)
Figure S3 F8 variants. This image shows the positions of the F8
variants that were observed in our dataset. Image modified from
Ge et al. and Hubbard et al.
Found at: doi:10.1371/journal.pgen.1001111.s003 (0.09 MB TIF)
Table S1 General characteristics for each genome.
Found at: doi:10.1371/journal.pgen.1001111.s004 (0.06 MB
DOC)
Table S2 Variants identified for each individual genome.
Found at: doi:10.1371/journal.pgen.1001111.s005 (0.04 MB
DOC)
Table S3 Overlap of SNVs identified by sequencing with those
that are included in the dbSNP database, HapMap, or are on the
Illumina 1M chip, version 1.
Found at: doi:10.1371/journal.pgen.1001111.s006 (0.06 MB
DOC)
Table S4 Overlap of dbSNP and SNVs identified by sequenc-
ing.
Found at: doi:10.1371/journal.pgen.1001111.s007 (0.05 MB
DOC)
Table S5 Number of indels identified in whole-genome
sequencing studies and in dbSNP.
Found at: doi:10.1371/journal.pgen.1001111.s008 (0.06 MB
DOC)
Table S6 Transition to transversion ratios and homozygote to
heterozygote ratios.
Found at: doi:10.1371/journal.pgen.1001111.s009 (0.04 MB
DOC)
Table S7 Comparison of transition to transversion ratios and
homozygote to heterozygote ratios.
Found at: doi:10.1371/journal.pgen.1001111.s010 (0.05 MB
DOC)
Table S8 Comparison of SNV calls made from whole-genome
sequence versus genotype data.
Found at: doi:10.1371/journal.pgen.1001111.s011 (0.05 MB
DOC)
Table S9 SNVs by their function and predicted number of
homozygotes.
Found at: doi:10.1371/journal.pgen.1001111.s012 (0.07 MB
DOC)
Table S10 Indels by their function and homozygosity.
Found at: doi:10.1371/journal.pgen.1001111.s013 (0.06 MB
DOC)
Table S11 Comparison of individual average number of coding
indels, restricted to exome captured regions and canonical genes
and transcripts.
Found at: doi:10.1371/journal.pgen.1001111.s014 (0.04 MB
DOC)
Table S12 Validating protein-truncating variants using Sanger
sequencing.
Found at: doi:10.1371/journal.pgen.1001111.s015 (0.05 MB
DOC)
Table S13 Causal variants of type A hemophilia observed in this
study.
Found at: doi:10.1371/journal.pgen.1001111.s016 (0.04 MB
DOC)
Table S14 Prioritization of all genes enriched for protein
truncating variants in hemophilia samples.
Found at: doi:10.1371/journal.pgen.1001111.s017 (0.04 MB
DOC)
Text S1 Supplementary methods.
Found at: doi:10.1371/journal.pgen.1001111.s018 (0.04 MB
DOC)
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